User profiles for P Kulanthaivel

Palaniappan Kulanthaivel

- Verified email at pyramidbio.com - Cited by 5431

P.Kulanthaivel

- Verified email at kongu.edu - Cited by 208

Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors

…, AD Fulford, TS Nguyen, R Martinez, P Kulanthaivel… - Cancer discovery, 2016 - AACR
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …

Balanol: a novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoides

P Kulanthaivel, YF Hallock, C Boros… - Journal of the …, 1993 - ACS Publications
Protein kinase C (PKC), a family of serine/threonine-specific kinases, plays a key role in cell
growth, metabolism, and differentiation. 1 Because the activated enzyme has been impli-…

Understanding disease–drug interactions in cancer patients: implications for dosing within the therapeutic window

DE Coutant, P Kulanthaivel, PK Turner… - Clinical …, 2015 - Wiley Online Library
The human inflammatory response can result in the alteration of drug clearance through
effects on metabolizing enzymes or transporters. In this article we briefly review the theory of …

Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an …

TJ Raub, GN Wishart, P Kulanthaivel, BA Staton… - Drug Metabolism and …, 2015 - ASPET
… Both inhibitors were substrates for xenobiotic efflux transporters P-glycoprotein and breast
cancer resistant protein expressed at the blood–brain barrier. Brain K p,uu values were less …

Selective metabolism of vincristine in vitro by CYP3A5

JB Dennison, P Kulanthaivel, RJ Barbuch… - Drug metabolism and …, 2006 - ASPET
… Statistical significance (p < 0.05) was determined using Student's t test or one-way analysis
… Barbuch, and P. Kulanthaivel, manuscript in preparation). The unusually large diamagnetic …

A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds

…, MMY Chen, P Kulanthaivel… - … A European Journal, 2009 - Wiley Online Library
Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus
megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 …

A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer

…, LF Stancato, R Bell, P Shi, P Kulanthaivel… - Clinical Cancer …, 2016 - AACR
Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment
and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, …

Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells

…, WJ Ehlhardt, DA Jackson, P Kulanthaivel… - Chemical research in …, 2003 - ACS Publications
… and/or repeated exposure to capsaicin has also been shown to cause a Ca 2+ -dependent
desensitization in peripheral sensory neurons due, in part, to depletion of substance P from …

Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening

…, G Zhu, RM Campbell, TS Park, P Kulanthaivel… - Eukaryotic …, 2004 - Am Soc Microbiol
… Streptavidin-coated PVT SPA beads and [ 33 P]ATP are the two most expensive components
of the SPA-based HTS and, furthermore, a large amount of 33 P radioactive waste is also a …

[HTML][HTML] A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients

SC Tate, AK Sykes, P Kulanthaivel, EM Chan… - Clinical …, 2018 - Springer
… ) relationship for p-Rb inhibition, the popPK model developed in this work was combined
with the previously developed pre-clinical semi-mechanistic PK/PD model [9] to simulate the p-…